{"id":"palonosetron-only","safety":{"commonSideEffects":[{"rate":"9","effect":"Headache"},{"rate":"5","effect":"Constipation"},{"rate":"3","effect":"Diarrhea"},{"rate":"2","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Palonosetron binds with high affinity and selectivity to 5-hydroxytryptamine type 3 (5-HT3) receptors, which are located on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By antagonizing these receptors, it prevents the emetic signal cascade triggered by chemotherapy, radiation, or post-operative conditions. It has a longer half-life and greater receptor binding affinity compared to earlier-generation 5-HT3 antagonists.","oneSentence":"Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:43.370Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Prevention of post-operative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT03386617","phase":"PHASE2","title":"AKY15-HK-301_NEPA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2018-02-27","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT06904235","phase":"PHASE2","title":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","status":"RECRUITING","sponsor":"Helsinn Healthcare SA","startDate":"2025-07-07","conditions":"Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy","enrollment":95},{"nctId":"NCT06840769","phase":"PHASE1","title":"A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers","status":"TERMINATED","sponsor":"Helsinn Healthcare SA","startDate":"2023-06-17","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT05315999","phase":"PHASE2","title":"Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care","status":"COMPLETED","sponsor":"Gerhild Becker","startDate":"2022-05-03","conditions":"Nausea, Vomiting, Pain","enrollment":30},{"nctId":"NCT01836705","phase":"PHASE1","title":"Effect of SAR302503 on ECG Activity in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-05","conditions":"Neoplasm Malignant","enrollment":60},{"nctId":"NCT06726291","phase":"PHASE4","title":"Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2024-02-26","conditions":"Endometrial Cancer","enrollment":84},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT03204279","phase":"PHASE2","title":"PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2017-08-31","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":67},{"nctId":"NCT06427681","phase":"EARLY_PHASE1","title":"An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Zhuhai Beihai Biotech Co., Ltd","startDate":"2024-05","conditions":"Bioavailability","enrollment":40},{"nctId":"NCT05841849","phase":"PHASE4","title":"Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-07","conditions":"Breast Cancer, Chemotherapy-induced Nausea and Vomiting","enrollment":1028},{"nctId":"NCT05690802","phase":"NA","title":"The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-05-16","conditions":"Nausea and Vomiting","enrollment":1060},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT05439798","phase":"PHASE3","title":"Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting","status":"UNKNOWN","sponsor":"Selcuk University","startDate":"2022-06-01","conditions":"Laparoscopic Surgery, Pediatrics, Nausea and Vomiting, Postoperative","enrollment":66},{"nctId":"NCT01363479","phase":"PHASE3","title":"An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-07","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":743},{"nctId":"NCT04585412","phase":"PHASE4","title":"Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)","status":"COMPLETED","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2020-08-17","conditions":"Chemotherapy-induced Nausea and Vomiting, Prophylaxis","enrollment":16},{"nctId":"NCT01054456","phase":"PHASE2","title":"A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-10-27","conditions":"Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC","enrollment":36},{"nctId":"NCT03008213","phase":"PHASE2","title":"Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV","status":"TERMINATED","sponsor":"Joseph Ma","startDate":"2017-01","conditions":"Chemotherapy Induced Nausea Vomiting","enrollment":4},{"nctId":"NCT00900757","phase":"PHASE2","title":"Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-08","conditions":"Malignant Glioma","enrollment":57},{"nctId":"NCT04060771","phase":"PHASE3","title":"Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery","status":"UNKNOWN","sponsor":"Universidade Federal Fluminense","startDate":"2018-08-01","conditions":"Anesthesia, Strabismus, PONV","enrollment":80},{"nctId":"NCT03862144","phase":"PHASE2","title":"NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2016-05-12","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":150},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":"Oncology","enrollment":426},{"nctId":"NCT02557035","phase":"PHASE3","title":"An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-10","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":441},{"nctId":"NCT00381862","phase":"PHASE2","title":"Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-06","conditions":"Colorectal Cancer, Nausea and Vomiting","enrollment":54},{"nctId":"NCT00661674","phase":"NA","title":"Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-04","conditions":"Substance-Related Disorders","enrollment":10},{"nctId":"NCT00895245","phase":"PHASE2","title":"Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","status":"TERMINATED","sponsor":"University of Washington","startDate":"2009-02","conditions":"Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx","enrollment":6},{"nctId":"NCT00684463","phase":"PHASE4","title":"Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04-11","conditions":"Neoplasms, Nausea, Vomiting","enrollment":59},{"nctId":"NCT00687011","phase":"PHASE4","title":"Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-10","conditions":"Neoplasms, Nausea, Vomiting","enrollment":118},{"nctId":"NCT02484911","phase":"PHASE3","title":"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-05","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":120},{"nctId":"NCT02468323","phase":"PHASE4","title":"Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia","status":"COMPLETED","sponsor":"Hospital de Base","startDate":"2015-10","conditions":"PONV","enrollment":150},{"nctId":"NCT02650479","phase":"PHASE1","title":"Study of the Effects of Intravenous Exenatide on Cardiac Repolarization","status":"COMPLETED","sponsor":"Intarcia Therapeutics","startDate":"2016-01","conditions":"Healthy Adult Male and Female Volunteers","enrollment":82},{"nctId":"NCT02445872","phase":"PHASE2","title":"Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-12","conditions":"Chemotherapy-Induced Nausea and Vomiting, Lung Cancer","enrollment":80},{"nctId":"NCT01074697","phase":"PHASE3","title":"Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2010-04","conditions":"Nausea, Vomiting, Genital Neoplasms, Female","enrollment":246},{"nctId":"NCT00952133","phase":"PHASE4","title":"Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-07","conditions":"PONV","enrollment":118},{"nctId":"NCT00828295","phase":"PHASE3","title":"Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2008-08","conditions":"Postoperative Nausea and Vomiting","enrollment":150},{"nctId":"NCT01442376","phase":"PHASE3","title":"Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-09","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":502},{"nctId":"NCT02205164","phase":"PHASE2","title":"Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients","status":"UNKNOWN","sponsor":"Associazione Salentina Angela Serra","startDate":"2011-10","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":134},{"nctId":"NCT01395901","phase":"PHASE3","title":"Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-06","conditions":"Postoperative Nausea and Vomiting","enrollment":670},{"nctId":"NCT00636805","phase":"PHASE2","title":"Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab","status":"TERMINATED","sponsor":"Duke University","startDate":"2008-05","conditions":"Brain Cancer","enrollment":63},{"nctId":"NCT00410488","phase":"NA","title":"Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Sarcoma, Nausea, Vomiting","enrollment":51},{"nctId":"NCT01482468","phase":"NA","title":"Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting","status":"UNKNOWN","sponsor":"Incheon St.Mary's Hospital","startDate":"2012-03","conditions":"Postoperative Nausea and Vomiting","enrollment":132},{"nctId":"NCT01169805","phase":"NA","title":"Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-08","conditions":"Laparoscopic Marsupialization of Renal Cyst","enrollment":105},{"nctId":"NCT00359567","phase":"PHASE3","title":"Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2006-07","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":1140},{"nctId":"NCT01018758","phase":"PHASE2","title":"Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Gruppo Italiano Studio Linfomi","startDate":"2006-07","conditions":"Chemotherapy-Induced Nausea and Vomiting, Non Hodgkin's Lymphoma","enrollment":86},{"nctId":"NCT00666783","phase":"PHASE2","title":"An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":208}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Palonosetron","Saline Solution"],"phase":"marketed","status":"active","brandName":"Palonosetron only","genericName":"Palonosetron only","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy, Prevention of post-operative nausea and vomiting (PONV), Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}